EGFR and non-small cell lung carcinoma: The survival time of high-RS patients was significantly shorter than that of low-RS patients (HR = 2.1, 95% CI = 1.51–2.91, P < 0.0001), suggesting that the two-gene signature had a generalized and adaptive capacity in predicting the prognosis of EGFR-WT NSCLC patients.